Pulmonary arterial hypertension   - CML - Chronic myeloid leukemia

             Pulmonary hypertension (PH) is a rare, but life-threatening, adverse event in patients treated with tyrosine kinase inhibitors (TKIs). PH can occur with any TKI used in CML but it is more frequent with dasatinib.

VIDEOS

What is pulmonary hypertension?
September 23, 2016, Royal Free London NHS Foundation Trust

Pulmonary Hypertension Explained Clearly by MedCram.com   
April  12, 2016,  MedCram - Medical Lectures Explained Clearly

Pulmonary Hypertension: A challenging cause of shortness of breath
December 28, 2011, Penn Medicine

                    

ARTICLES

TKIs Associated With Subclinical Pulmonary Hypertension in CML Patients
March 29, 2017, Cancer Network

TKIs Linked to Pulmonary Hypertension in CML
March 27, 2017, Chronic myeloid leukemia advisor

Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib
Mar 24, 2017, NCBI

Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity
2016, European Respiratory Journal

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
June 3, 2016, Leukemia

Prevalence of Pulmonary Hypertension in the General Population: The Rotterdam Study
June 23, 2015, PLOS  

                                          See also  Pleural effusion with CML
                            
                                           Return to the List of side effects
                               Return  to Managing Side Effects 
​    ​